Preregistration and Data Sharing Norms in Reagent Characterization Studies

What preregistration means in the context of a reagent characterization study

Preregistration means locking the study design, the primary endpoint, and the analysis plan in place before a single sample gets touched. It has nothing to do with where or whether results eventually appear in print. That confusion, preregistration mistaken for publication, comes up often enough that the distinction needs stating bluntly: preregistration happens before you pick up a pipette, publication happens after, and conflating them lets a lot of sloppy work hide behind a respectable-sounding word.

For a reagent characterization study, preregistration means writing down, in advance, which lots are being tested and how they were selected, which protein target and expression conditions apply (template concentration, reaction volume, temperature, duration), which yield or activity metric counts as the primary endpoint, and what statistical threshold defines acceptable lot-to-lot agreement. Skipping that step causes characterization to quietly turn into description after the fact: whatever endpoint looked best once the data were in hand gets reported as though it had been the plan all along. A result and a story about a result are different things. Preregistration is the only thing standing between them.

Funders are done treating this as optional. NIH's National Institute on Aging now builds requirements for documenting reagent and protocol provenance, and for validating research tools, directly into basic research grants. Labs still filing this under best-practice paperwork are going to find themselves out of step with where the funding actually points.

Lot-level performance data without a pre-specified measurement framework

Total-protein quantification has a blind spot: it counts inactive protein species right alongside active ones. Two lots reported at the same concentration by mass can behave completely differently in an assay, because mass and activity are not the same quantity. Treating them as interchangeable is where most characterization work goes wrong, quietly and early, before anyone notices the numbers were measuring the wrong thing.

A Bristol-Myers Squibb study comparing batches of recombinant soluble LAG-3 (sLAG3) shows the scale of the problem. Once the reagent was defined by its assay-specific active concentration, measured through calibration-free concentration analysis (CFCA), lot-to-lot coefficients of variation dropped by more than 600 percent relative to total protein concentration. The measurement framework, not the reagent, was driving most of the apparent variability. A bad CV on a spec sheet might mean a bad lot. That distinction matters: a bad CV on a spec sheet might mean a bad lot, or it might just as easily mean somebody picked the wrong assay to describe a perfectly good one, and treating those two failures as the same thing is a mistake.

Without a shared standard, different analysts pick different concentration methods and land on incompatible conclusions about the same lots. Cross-site comparison does not just get harder here; it becomes structurally impossible, because there is no common yardstick to translate one lab's number into another's. CFCA also reduces how sensitive ligand-binding assay calibration curves are to the order in which reagent lots get introduced, which matters directly for multi-site CFPS work, where reagent lot sequences vary across sites.

Open data sharing turning a characterization result from a supplier claim into a verifiable record

Every characterization study produces two things: a summary claim, something like "lot X yields Y mg/mL under Z conditions," which the raw data generates and supports. Only when both are available does the claim become something a third party can check, rather than something they have to take on faith.

That distinction carries more weight in CFPS than in most reagent categories, because reaction outcomes come out of the lysate lot, the energy module, and the DNA template acting together, all at once. A user who gets a worse result than expected has no way to diagnose why without the original conditions and measurements sitting in front of them. Guessing which of three interacting modules caused the shortfall, with no data trail to check against, is speculation dressed up as troubleshooting, and calling it anything else is generous.

That gap raises costs late in the process, and those costs are steep. Programs that carry poorly characterized reagents through early discovery tend to hit reproducibility failures right as they move toward preclinical work, which is the worst possible place in the pipeline to discover a reagent was never actually pinned down. The FAIR principles, findable, accessible, interoperable, reusable, spell out what "open" requires in practice, and they show up as the design target in the design-build-test-learn (DBTL) literature for automated CFPS workflows for exactly that reason.

Preregistered, openly documented characterization studies enabling meaningful cross-lab comparisons in CFPS

CFPS extract sources have moved well past E. coli. Wheat germ, insect cell, and human cell line extracts are all in active use now, each with its own post-translational modification profile and its own yield behavior. Comparing results across those platforms without a shared characterization standard is close to meaningless, since a difference in outcome could come from the platform, the lot, or the measurement, and nothing in an unstandardized dataset tells you which one.

High-throughput formats make the problem worse, not better. A 384-well plate run on an Echo 650 acoustic dispenser can throw off hundreds of data points in a single pass, and those results are only as reproducible as the documentation tying each one back to the reagent's actual state at the moment of the run. Recent work on AI-driven droplet screening of cell-free gene /* blocked */Nature Communications, 2025, DOI: 10.1038/s41467-025-58139-0), along with automated DBTL pipelines built on the Galaxy platform under FAIR principles, mark the leading edge of this shift. At that speed and volume, retrospective documentation does not work: there is no time to reconstruct conditions after the fact when a pipeline is producing results continuously.

Active learning loops inside DBTL cycles raise the stakes further still. Those loops pick the next round of experimental conditions based on prior data, and if that prior data is not open and structured the same way across batches, the algorithm ends up training on inputs that do not mean the same thing from one batch to the next. Garbage in, in that setting, does not just produce one bad prediction. It produces a bad prediction that reinforces itself over every subsequent round.

The particular challenge of characterizing CFPS reagents for difficult protein targets

CFPS earns its reputation on the targets hardest to express any other way: toxic proteins, membrane proteins, insoluble aggregation-prone constructs. Those same targets are exactly the ones where a plain yield number tells you the least, because a lot can produce plenty of protein and still produce protein that is misfolded, aggregated, or otherwise dead on arrival.

Membrane proteins make the problem obvious. Their hydrophobicity and structural complexity make isolation and reconstitution hard under the best conditions, and over-expression in living cells is often toxic to the host. Cell-free systems are frequently the only practical route to producing them, but that also means there is no in-cell benchmark sitting nearby to check the cell-free result against. The characterization has nothing external to validate against; it has to stand entirely on its own documentation.

A 2026 PNAS study on synthetic transmembrane β-barrels, expressed in a cell-free system alongside lipid vesicles, found that design strategies aimed only at stabilizing the native folded state led instead to misfolding and aggregation. Yield alone is not characterization for a membrane protein lot, and that study demonstrates why: folding state and assembly behavior in a membrane-mimetic environment have to be part of the documented outcome, not an afterthought tacked on if there is time. A protein language model in that same study beat traditional energy-based design methods at predicting which mutations would actually help, which points toward a future where machine-learning-guided protein design depends on rich, openly shared characterization data from the start. A model is only as good as the characterization record that trained it.

The contribution of reagent formulation transparency beyond data sharing alone

Open data tells a user what a reagent did in a given reaction. It says nothing about what the reagent actually is. Both pieces are necessary before anyone can diagnose an unexpected result, and having only one is like reading the outcome of an experiment without ever seeing the method section.

Undefined formulations make troubleshooting close to impossible by construction. If a lot underperforms and the formulation is a black box, a raw material may have changed, a process step may have drifted, or the measurement itself may have been off, and a user cannot tell which. All three look identical from the outside when the composition stays hidden.

Cost matters here too, and it cuts against the supplier's usual defense, not for it. Crude lysates run around three cents per microliter and scale economically all the way up to multi-kiloliter volumes, with production documented at up to 4.5 kL. That price point is a large part of what makes CFPS viable at scale, but the low cost travels together with compositional opacity, and that opacity makes lot comparison harder. A supplier does not get to treat that as an unrelated tradeoff. Reconstituted, PURE-type systems are fully defined and free of the background interference that comes with crude lysate, which makes them more tractable to characterize in principle, but commercial PURE-type kits typically do not publish their component concentrations. Being "defined" as a system does not automatically mean being transparent to the person actually running it, and suppliers should not get credit for the first while quietly skipping the second.

Designing a CFPS reagent characterization study that is both preregisterable and practically executable

A workable pre-specification checklist needs several things nailed down before the first reaction runs. Lot identity and provenance come first: lot number, preparation date, storage conditions, and any documented deviation from the standard prep. The primary endpoint has to be defined in advance too: yield by mass, activity by a named assay with a stated cutoff, or both, along with how each will be measured.

A reference lot or benchmark condition belongs in the plan, with a clear statement of what counts as acceptable agreement against it. The protein target needs justification, whether it is a standard reporter or a representative difficult target, and the folding or activity readout that applies to it should be spelled out rather than assumed. Reaction conditions, template format, template concentration, reaction volume, incubation time and temperature, any supplementation with chaperones, detergents, or non-canonical amino acids, all need to be locked down before day one. The statistical plan needs a replication number, a defined method for calculating lot-to-lot CV, and a pre-specified acceptable range, decided before anyone looks at a single result.

None of this needs inventing from scratch. CLSI EP26-A, built for clinical laboratory settings, offers a practical template that adapts reasonably well to reagent testing outside the clinic. Plate-format workflows using 384-well plates and acoustic dispensers generate data faster than anyone can document by hand, so the characterization plan has to specify, up front, how data gets captured and linked automatically to lot identity. The endpoint of the whole exercise should be FAIR-compliant deposition, raw data, not just summary statistics, sitting in a repository where lot identity is a field someone can actually search on. That is what makes meta-analysis across studies possible instead of theoretical.

Open characterization norms and expectations for reagent suppliers

A credible certificate of analysis for a CFPS reagent has a floor: purity, endotoxin level, lot-specific yield on at least one standard reporter protein, and storage or stability data. Missing any of those is a documented gap in the supplier's quality system. It should get treated as exactly that, not waved off as a formality.

Whether lot-level data gets published proactively or only handed over when someone asks is a useful test of where a supplier actually stands. A supplier that publishes QC data at the moment of lot release has committed to a different standard than one that produces it only under pressure, and that difference says more about how the company operates than anything in its marketing material.

Formulation documentation deserves the same scrutiny. Ask whether a reagent is described in enough detail to actually troubleshoot when something goes sideways: if it isn't, reproducibility failures will be hard to trace and even harder to fix. Reagents priced for high-throughput use, screening large variant libraries, running full 384-well plates, are implicitly promising reproducibility across many parallel reactions at once, and opacity in lot characterization undercuts the exact throughput advantage the pricing is supposed to deliver. A supplier selling for scale has to characterize for scale. Anything less asks the customer to absorb a risk the supplier was in a far better position to catch first.